| Nov 4 |
Editas Medicine GAAP EPS of -$0.75 misses by $0.02
|
| Nov 4 |
Editas: Q3 Earnings Snapshot
|
| Nov 4 |
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
|
| Oct 31 |
Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?
|
| Oct 28 |
Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for
|
| Oct 25 |
Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline
|
| Oct 24 |
Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More
|
| Oct 23 |
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
|
| Oct 22 |
Editas and Genevant team up to develop gene editing therapies
|
| Oct 22 |
EDIT Editas_Medicine_Strategic_Update_-_October_2024_-_FINAL
|
